Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 8:40 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 308 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: lipitor Clear all

Conditions: Healthy Participants
Interventions: Elecoglipron, Atorvastatin, Rosuvastatin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Glendale, California • Brooklyn, Maryland

Conditions: Myalgia, Hypercholesterolemia, Hyperlipidemia
Interventions: PPD10558, Atorvastatin, Placebo; Drug
Lead sponsor: Furiex Pharmaceuticals, Inc; Industry
Eligibility: 40 Years and older
Enrollment: 282 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 67
States / cities: Anniston, Alabama • Phoenix, Arizona • Huntington Park, California + 60 more

Conditions: Cardiovascular Disease, Cerebrovascular Accident, Coronary Heart Disease
Interventions: Atorvastatin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 35 Years to 75 Years
Enrollment: 8,600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2004
U.S. locations: 181
States / cities: Alabaster, Alabama • Birmingham, Alabama • Hoover, Alabama + 129 more

Conditions: Hypercholesterolemia
Interventions: Alirocumab, Lipid-Modifying Therapy (LMT); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 986 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 44
States / cities: Huntsville, Alabama • Tempe, Arizona • Bell Gardens, California + 39 more

Conditions: Inflammation
Interventions: Atorvastatin; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 108 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Hyperlipidemia
Interventions: Atorvastatin, Placebo to Atorvastatin, Placebo to Ezetimibe, Ezetimibe, Placebo to Evolocumab, Evolocumab; Drug · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 511 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 18
States / cities: Beverly Hills, California • Huntington Beach, California • Los Angeles, California + 15 more

Conditions: Nephrotic Syndrome, Hyperlipidemia
Interventions: Atorvastatin, Placebo; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 6 Years to 17 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 1999
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Healthy
Interventions: Atorvastatin; Drug
Lead sponsor: Ranbaxy Laboratories Limited; Industry
Eligibility: 18 Years to 66 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Healthy Participants
Interventions: AZD5004, Rosuvastatin, Erythromycin, Atorvastatin, Simvastatin, Repaglinide; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Brooklyn, Maryland

Conditions: Calcinosis, Arteriosclerosis, Hyperparathyroidism, Secondary
Interventions: calcium acetate, sevelamer, atorvastatin; Drug
Lead sponsor: Nabi Biopharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 203 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Drug-Interactions
Interventions: ecopipam HCl ~2mg/kg/day, Cohort 1 Probe Cocktail, Cohort 2 Probe Cocktail, Cohort 3 Probe Cocktail; Drug · Combination Product
Lead sponsor: Emalex Biosciences Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Dyslipidemias
Interventions: LY3202328, Placebo, Atorvastatin, Simvastatin; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 4
States / cities: Miami, Florida • Lenexa, Kansas • Marlton, New Jersey + 1 more

Conditions: Breast Cancer, Breast Tumors, Cancer of Breast
Interventions: Metformin, Atorvastatin, Breast surgery; Drug · Procedure
Lead sponsor: Columbia University; Other
Eligibility: 21 Years and older · Female only
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Cardiovascular Diseases
Interventions: Atorvastatin; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Acute Coronary Syndromes
Interventions: rosuvastatin calcium, atorvastatin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 825 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 52
States / cities: San Diego, California • Torrance, California • Bridgeport, Connecticut + 49 more

Conditions: Hypercholesterolemia, Familial
Interventions: Torcetrapib/atorvastatin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy
Interventions: Atorvastatin, MGL-3196; Drug
Lead sponsor: Madrigal Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Healthy
Interventions: Rosuvastatin, Atorvastatin, Simvastatin, Digoxin, Caffeine; Drug
Lead sponsor: Tobira Therapeutics, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Coronary Artery Disease, Atherosclerosis, Heart Attack
Interventions: Statin, Aspirin tablet, Nexlizet, LEQVIO, Vascepa, Jardiance, Colchicine; Drug
Lead sponsor: University of Louisville; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Healthy Controls
Interventions: Atorvastatin, Pneumovax 23, Placebo (lactose pill); Drug · Other
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 40 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Atherosclerosis
Interventions: Atorvastatin; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Saphenous Vein Graft Disease
Interventions: Atorvastatin 80 mg daily, Atorvastatin 10 mg daily; Drug
Lead sponsor: Boca Raton Regional Hospital; Other
Eligibility: 18 Years and older
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Boca Raton, Florida

Conditions: Hypertension, Hyperlipidemia
Interventions: Polypill (atorvastatin, amlodipine, losartan, and hydrochlorothiazide); Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 45 Years to 75 Years
Enrollment: 303 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Mobile, Alabama

Conditions: Breast Cancer, Lymphoma
Interventions: Atorvastatin, Placebo; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 21 Years to 100 Years
Enrollment: 279 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 51
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Chicago, Illinois + 35 more

Search by objective public record fields.

A Study to Investigate the Effect of Elecoglipron on Rosuvastatin and Atorvastatin in Healthy Participants

Study of the Safety and Tolerability Associated With PPD10558 Versus Atorvastatin in Patients Previously Intolerant to Statins Due to Statin-associated Myalgia (SAM)

A Study to Determine the Degree of Additional Reduction in CV Risk in Lowering LDL Below Minimum Target Levels

Open Label Study of Long Term Safety Evaluation of Alirocumab

Systemic Immunomodulatory Effects and Pharmacogenetics of Atorvastatin in Early Atherosclerosis

Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3

Pilot Study of Atorvastatin in Children With Chronic Hyperlipidemia Secondary to Nephrotic Syndrome

A Bioequivalence Study Of 80 Mg Atorvastatin Calcium Tablets Versus 80 Mg Lipitor® Tablets Under Fed Conditions

A Study to Investigate the Effect of AZD5004 on Rosuvastatin, Atorvastatin, Simvastatin, Repaglinide and the Effect of Erythromycin on AZD5004 in Healthy Participants

CARE-2 (Calcium Acetate [PhosLo®]/Sevelamer[Renagel®] Evaluation Study 2) for Heart Calcification in Dialysis Patients

Drug-Drug Interaction Study to Evaluate the Effects of Ecopipam on the Pharmacokinetics of Multiple Substrates

A Study to Evaluate LY3202328 in Overweight Healthy Participants and Dyslipidemia

Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer

Evaluation of Atorvastatin Treatment on Carotid Plaque.

LUNAR IIIb Study Comparing Rosuvastatin and Atorvastatin in Subjects With Acute Coronary Syndromes

Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Patients With Genetic High Cholesterol Disorder

Drug Interaction Study of MGL-3196 With Atorvastatin

Pharmacokinetic and Safety Study of Cenicriviroc and HMG-CoA Reductase Inhibitors, Caffeine and Digoxin

Aggressive Risk-Prevention Therapies for Coronary Atherosclerotic Plaque (ART-CAP)

The Effect of Short-term Atorvastatin Treatment on Immune Responses to Pneumovax 23

Evaluation of Atorvastatin on Atherosclerosis Composition

Aggressive Cholesterol Therapy to Inhibit Vein Graft Events After CABG (ACTIVE Trial)

The SCCS Polypill Pilot Trial

Preventing Anthracycline Cardiovascular Toxicity With Statins (PREVENT)